Neurxstem has built what is designed to mimic the activity of the human central nervous system - a novel, first of its type synthetic Neural Organoid Platfrom. Traditionally, work in the arena of CNS disease biology and pharmaceutical development have employed rodent model systems or single cell line in vitro model systems that many suggest do not - in clinical trials - translate to human efficacy. Anchored in what could be a transformational approach for studying human central nervous system disease biology, diagnostic development, and novel therapeutic discovery and development, the Neurxstem approach addresses the needs of potential clients for disease mechanism research, target identification, and toxicity, safety and efficacy testing of big Pharma in a "one stop" platform that is highly predictive of human neural physiology. Neurxstem personnel report having engineered two genetic, syndromic model of autism and Alzheimerâs disease showing highly significant results. The genetic fingerprints correlate well with known clinical manifestations of these patients, validating the utility of the proprietary process to create highly informative neural organoids for certain CNS disorders
